TSE:4506Pharmaceuticals
Hematology Pipeline Advances Could Be A Game Changer For Sumitomo Pharma (TSE:4506)
In December 2025, Sumitomo Pharma America presented updated Phase 1/2 clinical data at the 67th American Society of Hematology Annual Meeting in Orlando, highlighting its investigational oral menin inhibitor enzomenib for relapsed or refractory acute leukemia and PIM1 kinase inhibitor nuvisertib for relapsed or refractory myelofibrosis.
The promising response rates and favorable safety profiles reported for these two early-stage oncology candidates point to a strengthening hematology...